American pharmaceutical company Wyeth won dismissal of a lawsuit in Minnesota regarding allegations that its products Premarin and Prempro caused breast cancer in a woman.

According to the New York Times, the well-known pharmaceutical company that is a major producer of medicine for use during menopause was cleared in court of accusations that two of its products caused breast cancer in one woman.

The controversial situation started when Patricia Zandi alleged that she developed breast cancer after she had used Wyeth’s Premarin and Prempro hormone replacement therapies.

Wyeth announced Tuesday that Judge Goerge F. McGunnigle of state district court in Minneapolis ruled that the woman did not present any scientifically convincing evidence to support her theory, according to which she developed breast cancer after using the drugs, the Times reports.

The company stated that there was no “scientifically valid evidence” to support her claim.

Another court jury in Reno, Nevada, ruled two weeks ago that the above-mentioned drugs contributed to the development of breast cancer in the case of three women who were rewarded with no less than $134, 5 million.

Wyeth is facing 5,300 lawsuits because of the two products, from women who believe that they were harmed by the hormone replacement drugs. These drugs have been used by almost six million women to control the negative effects of menopause such as hot flashes and mood swings, before a study made public in 2002 the relation between the drugs and breast cancer, according to the Times.

In 2006, the two drugs earned Wyeth more than $1 billion in sales and they are still on the market, the paper reports.

Wyeth said in their defense that they conducted safety tests on the medicine and warned about potential risks, by including these on prescription labels and information sheets.